968 related articles for article (PubMed ID: 24267638)
21. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
Lu XH; Fleming SM; Meurers B; Ackerson LC; Mortazavi F; Lo V; Hernandez D; Sulzer D; Jackson GR; Maidment NT; Chesselet MF; Yang XW
J Neurosci; 2009 Feb; 29(7):1962-76. PubMed ID: 19228951
[TBL] [Abstract][Full Text] [Related]
22. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
[TBL] [Abstract][Full Text] [Related]
23. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
[TBL] [Abstract][Full Text] [Related]
24. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
[TBL] [Abstract][Full Text] [Related]
25. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
26. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice.
Oliveras-Salvá M; Macchi F; Coessens V; Deleersnijder A; Gérard M; Van der Perren A; Van den Haute C; Baekelandt V
Neurobiol Aging; 2014 Nov; 35(11):2625-2636. PubMed ID: 25037286
[TBL] [Abstract][Full Text] [Related]
27. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
28. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
Caudal D; Alvarsson A; Björklund A; Svenningsson P
Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
[TBL] [Abstract][Full Text] [Related]
29. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
[TBL] [Abstract][Full Text] [Related]
30. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
31. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
32. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
33. Unilateral intranigral administration of β-sitosterol β-D-glucoside triggers pathological α-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat.
Soto-Rojas LO; Martínez-Dávila IA; Luna-Herrera C; Gutierrez-Castillo ME; Lopez-Salas FE; Gatica-Garcia B; Soto-Rodriguez G; Bringas Tobon ME; Flores G; Padilla-Viveros A; Bañuelos C; Blanco-Alvarez VM; Dávila-Ayala J; Reyes-Corona D; Garcés-Ramírez L; Hidalgo-Alegria O; De La Cruz-López F; Martinez-Fong D
Acta Neuropathol Commun; 2020 Apr; 8(1):56. PubMed ID: 32321590
[TBL] [Abstract][Full Text] [Related]
34. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
[TBL] [Abstract][Full Text] [Related]
35. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
[TBL] [Abstract][Full Text] [Related]
36. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
[TBL] [Abstract][Full Text] [Related]
37. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
38. Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector.
Van der Perren A; Casteels C; Van Laere K; Gijsbers R; Van den Haute C; Baekelandt V
J Vis Exp; 2016 Feb; (108):53670. PubMed ID: 26967677
[TBL] [Abstract][Full Text] [Related]
39. Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression.
Pupyshev AB; Korolenko TA; Akopyan AA; Amstislavskaya TG; Tikhonova MA
Neurosci Lett; 2018 Apr; 672():140-144. PubMed ID: 29203207
[TBL] [Abstract][Full Text] [Related]
40. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
Karikari AA; McFleder RL; Ribechini E; Blum R; Bruttel V; Knorr S; Gehmeyr M; Volkmann J; Brotchie JM; Ahsan F; Haack B; Monoranu CM; Keber U; Yeghiazaryan R; Pagenstecher A; Heckel T; Bischler T; Wischhusen J; Koprich JB; Lutz MB; Ip CW
Brain Behav Immun; 2022 Mar; 101():194-210. PubMed ID: 35032575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
